← Back to Clinical Trials
Recruiting NCT06794970

NCT06794970 Tissue Study on the Chronic Active Humoral Rejection (cAMR) Population of Kidney Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06794970
Status Recruiting
Phase
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Condition Kidney Transplant
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2023-05-01
Primary Completion 2028-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2023-05-01 with a primary completion date of 2028-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study is tissue-based, retrospective and prospective, single-centre, non-sponsored. Primary objective: To examine patient and organ survival and eGFR variation in kidney transplant patients diagnosed histologically with cAMR.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Kidney transplant recipients * eGFR\>15 ml/min/1.73 sq m at the time of diagnosis of cAMR * cAMR diagnosis defined on the basis of the 2018 Banff Classification (17), made after 1/1/2018. * Obtaining Informed Consent to Participation. Exclusion Criteria: * Combined transplant patients (heart-kidney, liver-kidney or kidney-pancreas) * Histological evidence of concomitant disease (e.g. recurrence of original nephropathy or diagnosis of 'de novo' nephropathy, acute cellular rejection, polyomavirus BK nephropathy, other)

Contact & Investigator

Central Contact

Gaetano La Manna, MD

✉ gaetano.lamanna@unibo.it

📞 00390512144577

Principal Investigator

Gaetano La Manna, MD

PRINCIPAL INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions

Who can join the NCT06794970 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06794970 currently recruiting?

Yes, NCT06794970 is actively recruiting participants. Contact the research team at gaetano.lamanna@unibo.it for enrollment information.

Where is the NCT06794970 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06794970 clinical trial?

NCT06794970 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Gaetano La Manna, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology